FDA Approves New Indication for Wyeth's Tygacil (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia

March 24, 2009 -- Wyeth Pharmaceuticals, a division of Wyeth , announced today that the U.S. FDA approved TYGACIL (tigecycline), for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens

The details can be read here.